More stuff in via:packrati.us. Data Mining in the Deep, Dark Social Networks of Patients. Word to Pharma: Caveat Emptor. Yesterday, I posted the following tweet:
Financial Articles & Investing News. BOSTON (TheStreet) -- Contrary to popular opinion, I am capable of saying something nice about biotech stocks.
I'm not all doom and gloom. Newsnight - Venter: Artificial living cell will benefit humanity. Understanding Traffic Demographics - Google Grants Blog. Asda to sell cancer drugs at cost price - Times Online. Asda is to sell cancer drugs on a not-for-profit basis, as thousands of NHS patients continue to be denied medicines that are deemed too expensive.
The supermarket giant called on other pharmacists to follow its lead and lower the price of all cancer drugs that are prescribed privately, to give patients access to drugs that are not always available on the NHS. The move could save cancer patients thousands of pounds on the cost of treatments that may extend their lives by weeks, months or years, but which have been judged to be too expensive to be routinely available for free from the health service.
The move comes as the Government restated a pledge to make more expensive treatments available to NHS patients from April next year, with a £200 million fund to pay for cancer drugs. The lung cancer drug Iressa will be sold by Asda for £2,167.71 for a pack of 30. Advaxis Live Listeria Prostate Cancer Vaccine Heads for Clinic - NORTH BRUNSWICK, N.J.
(BUSINESS WIRE) Advaxis, Inc., (OTCBB: ADXS). Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials. The company is collaborating with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop ADXS31-142 in human trials. Following the completion of manufacturing trials, the company intends to conduct a Phase 1 study with Dr. Research / Projects / First Self-Replicating Synthetic Bacterial Cell / Overview. Genomic science has greatly enhanced our understanding of the biological world.
It is enabling researchers to "read" the genetic code of organisms from all branches of life by sequencing the four letters that make up DNA. Sequencing genomes has now become routine, giving rise to thousands of genomes in the public databases. Scientists Reach Milestone On Way To Artificial Life. Vertex Pharmaceuticals Twitter Guidelines. Upload & Share PowerPoint presentations and documents.
eStore - Shop for Personal Care and Home Care Products. Pfizer Oncology to Present New Clinical Data From Ten Molecules Across Multiple Tumor Types. Pfizer Inc. logo. Landis, Admitting Doping, Accuses Top U.S. Cyclists. 2010 ASCO Annual Meeting. Special Exceptions and Status Changes Abstract Policy Exceptions According to ASCO's Abstract Policy, abstracts submitted to the Annual Meeting are confidential from the time of submission until the specified embargo lift date and time when the data becomes publicly available.
Under extenuating circumstances, ASCO may grant a formal exception to its Abstract Policy. Abstract Policy Exceptions require advance approval by ASCO before the information is made public. To request an Abstract Policy Exception, please contact Laura Livingston at laura.livingston@asco.org or 571-483-1352. For general abstract status inquiries, please contact abstracts@asco.org . GoToWebinar : Webinars Made Easy. Award-Winning Web Casting & Online Seminar Hosting Software. Results from VeriStrat biomarker analysis of Phase III trial presented at European Lung Cancer Conference.
Published on May 3, 2010 at 2:51 AM Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland.
Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from treatment with erlotinib, a commonly prescribed oral therapy for advanced non-small cell lung cancer (NSCLC). Following treatment with erlotinib, patients in the group classified as "VeriStrat Good" had a median survival of 10.5 months compared to 4.0 months in the group classified as "VeriStrat Poor. " The study retrospectively applied the VeriStrat proteomic analysis to a subset of the patient population from the NCIC Clinical Trials Group study BR.21, a Phase III, multicenter trial of erlotinib versus placebo in previously treated patients with NSCLC. SOURCE Biodesix. How to Convert Your Facebook Superfans Into Brand Ambassadors. Last week, I explored the birth of the “superfan” in social media, drawing from the superfan concept at sporting events and pointing out some fan qualities that my company has observed on our clients’ Facebook Pages.
This week, I’m going to discuss how to harness the passion of the superfan in order to convert them into an ambassador for your brand. Once we had identified the superfans — the Facebook fans who not only liked a brand’s page but also participated and interacted with others on the page and even came back on a daily or near daily basis — we knew we had to do something more. Sure, we could give them a special gift or recognize them publicly in a status update saying “Thanks,” but was that it?
What’s so “social” about that? Transparency Blog: FDA Unveils Draft Proposals on Agency Disclosure Policies for Public Comment. Home > Transparency Posts > FDA Unveils Draft Proposals on Agency Disclosure Policies for Public Comment Today, as part of the second phase of the Transparency Initiative, the Transparency Task Force released 21 draft proposals about FDA’s disclosure policies.
FDA is asking for comments on the proposals for 60 days. Brands and the Dark Side of Social Media - HBS Faculty. By John Deighton | 8:19 AM May 18, 2010 Sarah Palin can turn a phrase.
Hers is not the style of Churchill or JFK; in fact, it’s quite the opposite. And that’s the point. Social media and bookmarking - Pharma Strategy Blog. One of the cool things about using social media sites such as Twitter is the myriad of interesting links on science and cancer related topics that fly by my stream every day. Clearly, the sheer volume means that you can't track them all or even read half of them, but maybe you can capture and search them later. Well, that was my simple thinking at least and the reason I connected the Packrati.us tool to Twitter and Delicious yesterday, thinking that would be a simple and neat solution (HT to William Gunn for the idea):
How Small Adjustments Via Telemedicine Can Make A Difference. May 19th, 2010 by AlanDappenMD in Primary Care Wednesdays Last week we examined how, in a typical practitioner’s day, he or she often needs to make adjustments in patients’ care to keep them on the path to getting –- or staying — healthy. Usually a face-to-face physical exam isn’t necessary to make accurate changes to a patient’s care regiment. Instead, all discussions can be done via a form of telemedicine, such as a phone call, email, or video-conferencing.
Literature search on risk factors for sarcoma: Pub... [BMC Res Notes. 2010] - PubMed result. Ex-NIH chief and Nobel winner returns to lead National Cancer Institute. President Obama has appointed Harold Varmus, a Nobel Prize-winning researcher and former director of the National Institutes of Health, to lead the National Cancer Institute, the White House announced Monday. Varmus, 70, president of Memorial Sloan-Kettering Cancer Center in Manhattan, will take charge of the roughly $5 billion-budget institute in mid-July. Scripps Chemistry Idea “Clicks” With Big Pharma, Seattle’s Integrated Diagnostics. Luke Timmerman5/19/10 One of the Nobel Prize winners at The Scripps Research Institute in San Diego has been saying for a decade that chemists would be better off doing the simple thing instead of the hard thing.
Now quite a few of the world’s top academic scientists and Big Pharma companies are starting to adopt K. Bookmark Sync and Search. The interesting dichotomy of oncology research vs clinical medicine - Pharma Strategy Blog. Biopharma execs predict a big spike in M&A deals. CPBM: Extremely Small Float Could Mean Big Profits For Investors - BioMedReports.com. Cancer Cell - Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate. To view the full text, please login as a subscribed user or purchase a subscription. Fox Chase Opens First Inflammatory Breast Cancer Clinic on the East Coast. Harold Varmus Provides Vision While Venting at ASCO Meeting : Oncology Times. When Harold Varmus, MD, presented his Science of Oncology Award Lecture at the this year's American Society of Clinical Oncology Annual meeting, he used the occasion to promote his open-access Public Library of Science (PLoS) project—and to criticize the American Association for Cancer Research for obstructing the flow of peer-reviewed information to PubMed Central, the National Institutes of Health's free digital archive of biomedical and life sciences journal literature.
JNCI J Natl Cancer Inst. Publication in the Journal of the National Cancer Institute Demonstrates KRX-0401 (Perifosine) Single-Agent Potential in Neuroblastoma Tumors. April 14, 2014. Olaparib Active Against Advanced Ovarian Cancer in Women with BRCA Mutations : Cancer News. Olaparib, an investigational targeted therapy, resulted in a 61.5% response rate among women with platinum-sensitive, advanced ovarian cancer and a BRCA gene mutation.
These results were recently published in the Journal of Clinical Oncology.[1] Although most ovarian cancer patients initially respond to platinum-based chemotherapy, most will eventually experience a return (relapse) of their cancer. Ovarian cancer patients who experience a relapse of their cancer after treatment with platinum-based chemotherapy are characterized as either platinum-sensitive (relapse/progression occurs more than six months after last treatment); platinum-resistant (relapse/progression occurs less than six months after last treatment); or platinum refractory (relapse/progression while undergoing treatment). Conference Calendar Update. A Two-Step Plan for Changing Your Bad Habits - Peter Bregman.
Heard & Scene: Women in Science Luncheon. Financial Articles & Investing News. (Updated with corrected FDA approval decision date for Avanir Pharmaceuticals, which is Oct. 30, not Oct. 27, as previously reported.) Nephrology Medical News about Renal cell carcinoma. New York City is so beautiful when it's just waking up. The Honeymoon is Over (or: Why I went back to the iPhone from the HTC Desire) The Price of Payola: Advertisers Spend $50M a Year on Legal Bribes to Bloggers. Dig the effects of subsidies on the "free market" of food. Compare to diabetes, hypertension trends: @pdenlinger.